Public Offering

Advertisement

cGxPJobs Banner

Savara Raises $149.5M to Advance Rare Lung Therapeutic Program

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...

By cGxPwire Editor
November 2, 2025

Read More

Praxis Secures $525M to Boost CNS Drug Development

BOSTON, October 16, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, has announced the successful pricing...

By cGxPwire Editor
October 17, 2025

Read More

Advertisement

cGxPJobs

Directory